The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The hepatic apelin system: A new therapeutic target for liver disease†
Open accessAbstract
UNLABELLED: Apelin is a peptide that plays an important role in heart physiology and pathophysiology, inflammation, and angiogenesis. We evaluated whether the endogenous apelin system is involved in the pathogenesis of the hepatic remodeling and cardiovascular and renal complications occurring in advanced liver disease. The circulating levels of apelin, the messenger RNA (mRNA) and protein expression of apelin and apelin receptor, the immunohistological detection of apelin and apelin receptor, and the effects induced by the chronic administration of an apelin receptor antagonist on fibrosis and vessel density were evaluated in rats with cirrhosis and ascites and in control rats. The serum levels of apelin in patients with cirrhosis were also measured. Apelin levels were higher in rats with cirrhosis than in controls. Apelin mRNA showed a four-fold rise only in hepatic tissue, but not in the lung, heart, or kidney of rats with cirrhosis. These animals also showed hepatic apelin receptor mRNA levels 300 times higher than controls. Apelin was highly expressed by stellate cells, whereas apelin receptor was overexpressed in the hepatic parenchyma of animals with cirrhosis. Rats with cirrhosis treated with the apelin receptor antagonist showed diminished hepatic fibrosis and vessel density, improved cardiovascular performance, and renal function and lost ascites. Human patients also showed a marked increase in apelin levels. CONCLUSION: The selective hepatic activation of the apelin system, together with the drop in fibrosis and neoangiogenesis and the improvement in cardiovascular and excretory function resulting from apelin receptor blockade, points to the hepatic apelin system as a novel therapeutic target in liver disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apelin has been shown to be involved in glucose metabolism disorders and in hepatic fibrosis [52,53].”
From Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats (2015) · cites this paper as [53]
Citations
Cites
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor
Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.-X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9489 · Cited by 1,684
Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigné, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpéné, C., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1427 · Cited by 910
The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism
Tatemoto, K., Takayama, K., Zou, M.-X., Kumaki, I., Zhang, W. Y., KUMANO, K., & Fujimiya, M. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00236-1 · Cited by 640
Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility
Szokodi, I., Tavi, P., Földes, G., Voutilainen-Myllylä, S., Ilves, M., Tokola, H., Pikkarainen, S., Piuhola, J., Rysä, J., Tóth, M., et al. (2002) · Circulation Research · doi:10.1161/01.res.0000033522.37861.69 · Cited by 625
Molecular properties of apelin: tissue distribution and receptor binding
Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., Nishizawa, N., Kitada, C., Onda, H., Nishimura, O., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00143-9 · Cited by 521
Molecular and Functional Characteristics of APJ
Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908417199 · Cited by 488
Ishida, J., Hashimoto, T., Hashimoto, Y., Nishiwaki, S., Iguchi, T., Harada, S., Sugaya, T., Matsuzaki, H., Yamamoto, R., Shiota, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404149200 · Cited by 411
Mota, N. D., Goazigo, A. R.-L., Messari, S. E., Chartrel, N., Roesch, D. M., Dujardin, C., Kordon, C., Vaudry, H., Moos, F., & Llorens‐Cortés, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403518101 · Cited by 377
Cox, C. M., D'Agostino, S. L., Miller, M. K., Heimark, R. L., & Krieg, P. A. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.04.452 · Cited by 338
Kleinz, M. J., & Davenport, A. P. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.11.002 · Cited by 297
Apelin Has In Vivo Inotropic Effects on Normal and Failing Hearts
Berry, M. F., Pirolli, T. J., Jayasankar, V., Burdick, J., Morine, K., Gardner, T. J., & Woo, Y.-P. J. (2004) · Circulation · doi:10.1161/01.cir.0000138382.57325.5c · Cited by 278
Kidoya, H., Ueno, M., Yamada, Y., Mochizuki, N., Nakata, M., Yano, T., Fujii, R., & Takakura, N. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601982 · Cited by 270
Li, L., Yang, G., Li, Q., Tang, Y., Yang, M., Yang, H., & Li, K. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-948309 · Cited by 268
Tugues, S., Fernández‐Varo, G., Muñoz, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W., & Morales‐Ruiz, M. (2007) · Hepatology · doi:10.1002/hep.21921 · Cited by 263
Self-citationModification of the Terminal Residue of Apelin-13 Antagonizes Its Hypotensive Action
Lee, D. K., Saldivia, V., Nguyen, T., Cheng, R., George, S. R., & O’Dowd, B. F. (2004) · Endocrinology · doi:10.1210/en.2004-0359 · Cited by 256
TNFα up‐regulates apelin expression in human and mouse adipose tissue
Daviaud, D., Boucher, J., Gesta, S., Dray, C., Guigné, C., Quilliot, D., Ayav, A., Ziegler, O., Carpéné, C., Saulnier‐Blache, J. S., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5243fje · Cited by 219
Apelin (65‐77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells
Masri, B., Morin, N., Cornu, M., Knibiehler, B., & Audigier, Y. (2004) · The FASEB Journal · doi:10.1096/fj.04-1930fje · Cited by 211
Doğru, T., Sönmez, A., Taşçı, İ., Bozoğlu, E., Yılmaz, M. İ., Genç, H., Erdem, G., Gök, M., Bingöl, N., Kılıç, S., et al. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.07.031 · Cited by 201
Apelin (65–77) Activates Extracellular Signal-Regulated Kinases via a PTX-Sensitive G Protein
Masri, B., Lahlou, H., Mazarguil, H., Knibiehler, B., & Audigier, Y. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6230 · Cited by 172
The G Protein-Coupled Receptor Agtrl1b Regulates Early Development of Myocardial Progenitors
Scott, I. C., Masri, B., D’Amico, L., Jin, S., Jungblut, B., Wehman, A. M., Baier, H., Audigier, Y., & Stainier, D. Y. R. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.01.012 · Cited by 171
Hypoxia inducible factor regulates the cardiac expression and secretion of apelin
Ronkainen, V., Ronkainen, J. J., Hänninen, S. L., Leskinen, H. K., Ruas, J. L., Pereira, T., Poellinger, L., Vuolteenaho, O. J., & Tavi, P. (2007) · The FASEB Journal · doi:10.1096/fj.06-7294com · Cited by 168
Low Plasma Apelin Levels in Newly Diagnosed Type 2 Diabetes Mellitus
Erdem, G., Doğru, T., Taşçı, İ., Sönmez, A., & Tapan, S. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-1004564 · Cited by 127
Endocannabinoids and liver disease† ‡
Jiménez, W. (2005) · Hepatology · doi:10.1002/hep.20714 · Cited by 74
Self-citationNitric Oxide Synthase 3-Dependent Vascular Remodeling and Circulatory Dysfunction in Cirrhosis
Fernández‐Varo, G., Ros, J., Morales‐Ruiz, M., Cejudo–Martín, P., Arroyo, V., Solé, M., Rivera, F., Rodés, J., & Jiménez, W. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64331-3 · Cited by 74
Self-citationPlasma Apelin is Lower in Patients with Elevated LDL-Cholesterol
Taşçı, İ., Doğru, T., Naharcı, M. İ., Erdem, G., Yılmaz, M. İ., Sönmez, A., Bingöl, N., Kilic, S., Bingöl, S., & Erikci, S. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-971067 · Cited by 66
LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia
Taşçı, İ., Erdem, G., Özgür, G., Tapan, S., Doğru, T., Genç, H., Açıkel, C., Özgürtaş, T., & Sönmez, A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.030 · Cited by 54
Horiuchi, Y., Fujii, T., Kamimura, Y., & Kawashima, K. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.08.029 · Cited by 49
Sung, S., Chuang, S., Sheu, W. H., Lee, W., Chou, P., & Chen, C.-H. (2008) · Hypertension Research · doi:10.1291/hypres.31.633 · Cited by 24
Ros, J., Fernández‐Varo, G., Muñoz, J., Arroyo, V., Rodés, J., Gunnet, J. W., Demarest, K. T., & Jiménez, W. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706375 · Cited by 14
Self-citationExperimental Models of Cirrhosis and Ascites
Clària, J., & Jiménez, W. (2005) · doi:10.1002/9780470987476.ch17 · Cited by 11
Self-citationNitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis
Morales‐Ruiz, M., & Jiménez, W. (2005) · doi:10.1002/9780470987476.ch8 · Cited by 5
Self-citation
Cited by
Sorted by citations
Adipokines in liver diseases #
Marra, F., & Bertolani, C. (2009) · Hepatology · doi:10.1002/hep.23046 · Cited by 468
Adipokines in nonalcoholic fatty liver disease
Pοlyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2015.11.006 · Cited by 369
The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis
O’Carroll, A., Lolait, S. J., Harris, L. E., & Pope, G. R. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0227 · Cited by 339
Adipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Chakaroun, R., Raschpichler, M., Klöting, N., Oberbach, A., Flehmig, G., Kern, M., Schön, M. R., Shang, E., Lohmann, T., Dreßler, M., et al. (2011) · Metabolism · doi:10.1016/j.metabol.2011.10.008 · Cited by 234
Metadata
- Authors
- Principe, A., Melgar‐Lesmes, P., Fernández‐Varo, G., del Arbol, L. R., Ros, J., Morales‐Ruiz, M., Bernardi, M., Arroyo, V., & Jiménez, W.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Corresponding author
- Jiménez, Wladimiro
- ORCID
- Venue
- Hepatology
- Published
- 2008-10
- Volume
- 48
- Issue
- 4
- Pages
- 1193-1201
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1978999795
- Cited by
- 127
- References
- 32
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 7 · 2020: 11 · 2019: 9 · 2018: 7 · 2017: 7 · 2016: 6 · 2015: 17 · 2014: 10 · 2013: 7 · 2012: 9
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- apelin, apelin receptor, liver cirrhosis, liver fibrosis, ascites, hepatic stellate cells, neoangiogenesis, cardiovascular complications, renal function, advanced liver disease, therapeutic target
- MeSH terms
- Apelin, Adult, Animals, Blood Pressure, Carbon Tetrachloride, Carrier Proteins, Disease Models, Animal, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Renin-Angiotensin System, RNA, Messenger, Sympathetic Nervous System, Vascular Resistance, Case-Control Studies, Rats, Wistar, Intercellular Signaling Peptides and Proteins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
